Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Empagliflozin 25 mg tablet vs Jardiance 25 mg in healthy Thai volunteers under fasting
TCTR20250228006Phase 1Unknown
- Sponsor
- Bio-innova
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence. Status: unknown.
02
Drugs
empagliflozin
Beyond the preview
Go deeper on TCTR20250228006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250228006.